Welcome to This Week in Dermatology. This week we're covering 8 notable papers spanning acne management, new approaches to inflammatory skin disease, drug-induced bullous pemphigoid, and the standardization of teledermatology. Let's dive in. [PAUSE] Acne Management: Addressing Patient Concerns [PAUSE] We begin with two papers that address common and persistent questions in acne management. First,…

This week's papers:

Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delay. — Journal of the American Academy of Dermatology 2026
A distinct psoriasis-atopic dermatitis overlapping phenotype in adults with dual type 2 and type 3 immune features and favorable response to JAK1 inhibition. — Journal of the American Academy of Dermatology 2026
Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series. — Acta dermato-venereologica 2026
European Expert Consensus on Essential Variables for Teledermatological Assessment of Skin Tumours. — Acta dermato-venereologica 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials. — Acta dermato-venereologica 2026
Baricitinib versus Hydroxychloroquine for Cutaneous Lichen Planus: An Assessor-Blind Randomized Clinical Trial. — Clinical and experimental dermatology 2026
Isotretinoin Treatment in Adolescence and Adult Height. — JAMA dermatology 2026
Diet and acne: Facts and controversies. — Journal of the European Academy of Dermatology and Venereology : JEADV 2026